ARCT: Near-term clinical milestones and regained vaccine control drive strong commercial prospects
The session highlighted differentiated mRNA technologies, a robust rare disease pipeline, and near-term milestones including a phase II data readout for OTC deficiency and a pivotal CF program decision in Q4. Strategic partnerships and regained vaccine control position the company for commercial gr…